A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
- Autoimmune Disorder
- Rheumatoid Arthritis
Terminated
- Riyadh
NCT02616328 ML29936
Trial Summary
This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.
A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating the Efficacy and Safety of Using Tocilizumab (TCZ) for Confirmed Rheumatoid Arthritis (RA) Patients In Clinical Practice
Eligibility Criteria
- Diagnosed with moderate-to-severe active rheumatoid arthritis (RA) for over 3 months
- Started on tocilizumab, with or without previous history of biological treatment
- Pregnant or lactating women
- Treated with an investigational drug within 30 days prior to initiation of study drug
- Having a condition that, in the opinion of the investigator, could compromise the participant's safety or interfere with the study results
For the latest version of this information please go to www.forpatients.roche.com